Clinical efficacy of entecavir in treatment of hepatogenous diabetes

Objective To observe the clinical efficacy of entecavir in the treatment of hepatogenous diabetes(HD).Methods A retrospective analysis was performed on the clinical data of 72 HD patients,who were divided into treatment group(n=36) and control group(n=36).Both groups were given diabetic diet and received liver-protecting treatment,symptomatic treatment,and supportive treatment.In addition,the treatment group received oral entecavir(0.5 mg) once daily.The therapeutic effect was assessed after 52 weeks of treatment;the serum hepatitis B virus(HBV) DNA level,liver function(alanine aminotransferase,aspartate aminotransferase,total bilirubin,and albumin),blood glucose,and glycosylated hemoglobin were measured before and after treatment.The two groups were compared by t test(for measurement data) and chi-square test(for numeration data).Results After 52 weeks of treatment,29(80.56%) of the patients in treatment group had virological response,versus 7(19.44%) of those in control group(χ2 = 18.00,P0.01);26(72.22%) of the patients in treatment group had liver function recovery and controlled diabetes,versus 16(44.44%) of those in control group(χ2=5.774,P0.05).The treatment group showed significant improvements in liver function and blood glucose after treatment(P0.05);the treatment group had significantly lower glycosylated hemoglobin and fasting blood glucose than the control group(P0.01).Conclusion In the treatment of HBV DNA-positive hepatitis B cirrhosis with HD,entecavir not only can effectively inhibit the replication of viral DNA and promote the recovery of liver function,but also can effectively control HD.